Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azelastine + interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Xinxiang Medical College
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intranasal
01
Overview
Azelastine + interferon alfa-2b is an investigational combination therapy delivered as a thermosensitive gel nasal spray. It is being developed for the treatment of chronic rhinosinusitis, specifically during acute phases. The combination consists of azelastine, a selective H1-receptor antagonist with antihistamine and anti-inflammatory properties, and interferon alfa-2b, a recombinant cytokine with antiviral and immunomodulatory activity. The thermosensitive gel formulation allows for a transition from a liquid to a soft gel upon contact with the nasal mucosa, facilitating the sustained release of the active ingredients. This dual combination is being evaluated by the First Affiliated Hospital of Xinxiang Medical College in Phase 1 clinical trials, often as a comparator or component of a broader regimen including mesenchymal stem cell-derived exosomes.
- Other names
- azelastine and recombinant human interferon α-2b nasal sprayazelastine + interferon alpha-2b
02
Targets
CaV (Voltage-gated calcium channel protein complex)HRH1 (Histamine H1 Receptor)ARF1 (ADP-ribosylation factor 1)IFNAR (Immune system modulation via type I interferon receptor)HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on azelastine + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azelastine + interferon alfa-2b.